Pennsylvania is currently home to 3447 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Prospective Global Registry for the Study of Chronic Total Occlusion Intervention
NCT02061436
Recruiting
Percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) is increasingly being performed in patients with advanced coronary artery disease, but there is limited information on the techniques utilized and the procedural outcomes. The goal of this multicenter, investigator initiated registry is to collect information on treatment strategies and outcomes of consecutive patients undergoing CTO PCI among various participating centers. The information collected will be used to deter... Read More
Gender:
All
Ages:
All
Trial Updated:
03/08/2022
Locations: University of Pittsburgh Medical Center Presbyterian, Pittsburgh, Pennsylvania
Conditions: Coronary Artery Disease
Register for Updates
Strategy Training and Pets to Promote Stroke Survivor's Cognitive Performance and Community Participation
NCT05098730
Recruiting
The study will administer an intervention called strategy training to adult stroke survivors living in the community who do and do not have pets, and will examine the role of a pet in promoting cognitive performance and community participation outcomes.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2022
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Stroke
Register for Updates
KRT-232 and TKI Study in Chronic Myeloid Leukemia
NCT04835584
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI). This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/04/2022
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Chronic Myeloid Leukemia
Register for Updates
Efficacy Of Trimrox On Body Recomposition And Weight Management (TRCAP21)
NCT05283525
Recruiting
Protocol Number: VNI/121/TrimRox: A unique stimulant- and sugar-free TRCAP21 Prodosomed® nutraceutical formulation, TrimROXTM, has been developed in a cGMP and NSF-certified manufacturing facility that is CFR-111 A compliant as well as having a BRC A rating, ensuring compliance with the Global Food Safety Initiative (GFSI). The investigators developed a stimulant- and sugar-free TRCAP21 Prodosomed® nutraceutical technology that effectively addresses directly and indirectly all the contributing... Read More
Gender:
All
Ages:
Between 30 years and 70 years
Trial Updated:
03/03/2022
Locations: Dr Bruce S. Morrison, Huntingdon Valley, Pennsylvania
Conditions: Body Weight Changes
Register for Updates
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
NCT03257033
Recruiting
The study is a multi-center, un-blinded, randomized control study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/23/2022
Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
Conditions: Locally Advanced Pancreatic Cancer
Register for Updates
Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19
NCT04935476
Recruiting
This is a multi-center, randomized, triple-blind, placebo-controlled (RCT) study to evaluate the efficacy and safety of Dapsone in older adults, and/or in adult patients (≥40yrs of age) with at least one high-risk comorbidity, among those with confirmed SARS-CoV-2 infection. 3000 infected patients diagnosed with COVID-19, non-hospitalized at the time of enrollment, meeting all inclusion and no exclusion criteria will be randomized (1:1 allocation ratio) to receive either Dapsone or placebo tabl... Read More
Gender:
All
Ages:
40 years and above
Trial Updated:
02/22/2022
Locations: Temple University Hospital, Philadelphia, Pennsylvania
Conditions: COVID-19
Register for Updates
PEN-866 in Patients With Advanced Solid Malignancies
NCT03221400
Recruiting
Protocol PEN-866-001 is an open-label, multi-center, first-in-human Phase 1/2a study evaluating PEN-866 in patients with advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/16/2022
Locations: Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus, Adenocarcinoma of the Pancreas, Advanced Cancer, Solid Tumor, Solid Carcinoma, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Vulva, Squamous Cell Carcinoma of the Penis, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma
Register for Updates
Shared-Decision Making for Hydroxyurea
NCT03442114
Recruiting
The goal of the study is to understand how best to help parents of young children with sickle cell disease and their clinicians have a shared discussion about hydroxyurea (one that takes into account medical evidence and parent values and preferences). The study will compare two methods to help clinicians facilitate this-a clinician pocket guide and a clinician hydroxyurea shared decision making toolkit-in a group of parents of children ages 0-5 with sickle cell disease. The investigators hope t... Read More
Gender:
All
Ages:
Between 1 month and 5 years
Trial Updated:
02/09/2022
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Sickle Cell Anemia, Children, Only
Register for Updates
MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study
NCT03545607
Recruiting
A Phase 3 study to examine the safety and effectiveness of the allogeneic, adult stem cell investigational product, MultiStem, in adults who have suffered an acute ischemic stroke in the previous 18-36 hours.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/08/2022
Locations: Athersys Investigational Site 107, Hershey, Pennsylvania
Conditions: Ischemic Stroke
Register for Updates
Prevention of Obesity in Infants of Overweight and Obese Women
NCT04782063
Recruiting
Maternal and childhood obesity have dramatically increased and continue to present a significant health problem. Studies show that offspring of overweight (body mass index, BMI >25-29.9) and obese (BMI ≥30) women are at increased risk of newborn and age 1-year adiposity, and infant adiposity predicts childhood and adult obesity. The investigators hypothesize that infants of overweight/obese (OW/OB) mothers have both relative hyperphagia and are provided human milk with increased caloric composit... Read More
Gender:
Female
Ages:
Between 16 years and 50 years
Trial Updated:
02/04/2022
Locations: Penn State College of Medicine, Hershey, Pennsylvania
Conditions: Infant Obesity
Register for Updates
NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection
NCT04452565
Recruiting
This Phase 2/3 trial evaluates four treatment strategies for non-critically ill hospitalized participants (not requiring ICU admission and/or mechanical ventilation) with SARS CoV-2 infection, in which participants will receive NA-831 or Atazanavir with or without Dexamethasone.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/31/2022
Locations: Coronavirus Research Institute-Testing Site, Philadelphia, Pennsylvania
Conditions: Coronavirus Infection, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome Coronavirus 2
Register for Updates
Sorrel 25R Injector - Sorrel Clinical Study Protocol
NCT05221333
Recruiting
A prospective, open-label, single-center pilot study to evaluate the performance, safety and usability of the investigational SWI Device in healthy volunteers.
Gender:
All
Ages:
Between 18 years and 40 years
Trial Updated:
01/20/2022
Locations: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Conditions: Injection Site, Injection Site Reaction, Injection Site Irritation
Register for Updates